⌘K
t
Solvonis Therapeutics plc confirmed on 31 October 2025 its total issued share capital and voting rights as 6,806,403,493 Ordinary Shares. This figure includes an amendment correcting the number of shares to be issued and admitted from a previously announced 26,636,362 to 23,636,362. The Company holds no Ordinary Shares in treasury.
| Date | 31 Oct 2025 |
| Time | 15:59:40 |
| Category | Capital structure |
| ID | 7597F |
31 October 2025
Solvonis Therapeutics plc
("Solvonis" or the "Company")
Total Voting Rights
Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel medicines for high-burden central nervous system ("CNS") disorders, confirms that the Company's issued share capital as at the date of this announcement comprises 6,806,403,493 Ordinary Shares with one voting right each. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of Ordinary Shares and voting rights in the Company is 6,806,403,493.
This includes an amendment to the issue of shares announced on 31 October 2025 where the correct figure to be issued and admitted is 23,636,362. The original figure announced was 26,636,362.
The above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company.
Enquiries:
|
Solvonis Therapeutics plc |
anthony@solvonis.com |
|
Anthony Tennyson, CEO & Executive Director |
|
|
|
|
|
Singer Capital Markets (Corporate Broker) Phil Davies +44 (0) 20 7496 3000 |
|